Cagrilintide: The Amylin Analogue Behind CagriSema

Cagrilintide is the reason CagriSema exists. It is a long-acting analogue of amylin — a hormone co-secreted with insulin by pancreatic beta cells — and it acts on a pathway entirely separate from the GLP-1 receptor that semaglutide, tirzepatide and retatrutide all engage.

That separation is the whole commercial and scientific argument. Two non-overlapping mechanisms can be combined without one saturating the other.

What amylin does

Amylin is released alongside insulin after eating. Its recognised physiological roles are slowing gastric emptying, suppressing inappropriate glucagon release after meals, and contributing to satiety signalling in the brainstem.

Native amylin is difficult to use as a drug — it aggregates readily and has a short half-life. Cagrilintide is engineered around both problems, with acylation that extends its duration enough for once-weekly administration.

The phase 2 monotherapy trial

A multicentre, randomised, double-blind, placebo- and active-controlled dose-finding phase 2 trial published in The Lancet in 2021 tested once-weekly cagrilintide across a dose range in people with overweight and obesity, with liraglutide 3.0 mg as the active comparator.

• Once-weekly dosing was viable, which was the primary engineering question for an amylin analogue.

• Weight reduction increased with dose across the range tested.

• Gastrointestinal effects dominated the tolerability profile — nausea in particular, the same pattern seen across gut-hormone drugs.

• It was assessed against an active comparator, not only placebo, which is a stronger design than most phase 2 obesity trials.

Combination with semaglutide

A separate 2021 Lancet paper examined concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg, reporting safety, tolerability, pharmacokinetics and pharmacodynamics.

That study is the origin of CagriSema. It established that the two could be given together without pharmacokinetic interference — the necessary precondition for developing them as a fixed combination. The combination has since moved into a large phase 3 programme.

The CagriSema guide covers the combination product specifically.

Where it stands

Cost

Across the listings tracked by Peptide Library, cagrilintide runs at a median of about $13.25 per milligram — the highest of any peptide in the top-tracked set, with a typical range from roughly $7.90 to $29.35. That premium is characteristic of compounds that are recent and thinly supplied.

Current pricing sits on the vendor comparison, and the full picture on peptide pricing is in the cost guide.

What the evidence does not cover

• Long-term outcomes. Phase 2 trials establish dose-response and short-term tolerability, not cardiovascular or mortality outcomes.

• Use outside the trial populations. The published work is in overweight and obesity, with defined inclusion criteria.

• Combination with anything other than semaglutide. Pairing cagrilintide with tirzepatide or retatrutide has no published pharmacokinetic data at all.

• Unsupervised titration. The dose-finding design existed precisely because the right dose was not obvious.